Why is pancreatic cancer so lethal?

Pancreatic cancer has a nearly 1:1 incidence-to-mortality ratio because: most cases are diagnosed at advanced (locally advanced or metastatic) stage when surgery — the only cure — is impossible; it is biologically aggressive with rapid growth and early lymph node and liver metastasis; the dense fibrous stroma surrounding tumour cells limits drug delivery; and the molecular drivers (KRAS mutations present in >90% of tumours) were until recently undruggable. The 5-year survival of 12% overall (and <5% at metastatic stage) is the poorest of any major cancer.

What causes pancreatic cancer?

Risk factors: tobacco smoking (most important modifiable factor — 2-3 fold increased risk); chronic pancreatitis (10-fold increased risk); type 2 diabetes (2-fold risk — bidirectional relationship); obesity; heavy alcohol use; family history of pancreatic cancer; hereditary syndromes (BRCA1/2, Lynch syndrome, hereditary pancreatitis — PRSS1 mutations, SPINK1); and high-fructose diet (possible). Approximately 10% of pancreatic cancers are hereditary.

What are the symptoms?

Early pancreatic cancer is entirely asymptomatic — symptoms only appear when the tumour is large enough to cause biliary or duodenal obstruction, or when it has metastasised. Symptoms: painless jaundice (from bile duct obstruction — actually a relatively favourable sign indicating a ductal tumour amenable to surgery); abdominal or back pain (from retroperitoneal invasion — indicates unresectable disease); weight loss; new-onset diabetes (particularly in older patients without other risk factors — a potential early warning); and nausea.

Can pancreatic cancer be detected early?

Currently, there is no validated screening test for average-risk individuals. CA 19-9 lacks specificity for early detection. High-risk surveillance — annual MRI/MRCP and endoscopic ultrasound (EUS) — is recommended for individuals with >5% lifetime risk: BRCA1/2, PALB2, ATM, MLH1/MSH2/MSH6 mutation carriers; hereditary pancreatitis; Peutz-Jeghers syndrome; and familial pancreatic cancer kindreds. Liquid biopsy (ctDNA, cell-free DNA) and AI-based imaging analysis are research strategies for early detection.

What is the Whipple procedure?

Pancreaticoduodenectomy (the Whipple procedure) removes the head of the pancreas, duodenum, gallbladder, lower bile duct and sometimes part of the stomach — the only curative surgery for pancreatic head cancer (70-80% of PDACs). It is applicable to approximately 15-20% of patients at diagnosis. In high-volume specialist centres (>20 Whipple procedures/year), operative mortality is approximately 3-5%; 5-year survival after R0 resection (clear margins) reaches 20-25%.

What chemotherapy is used?

Metastatic pancreatic cancer: FOLFIRINOX (oxaliplatin + irinotecan + leucovorin + 5-FU) achieves median OS 11 months (PRODIGE 4 trial) in fit patients; gemcitabine + nab-paclitaxel achieves median OS approximately 8.5 months and is better tolerated in less fit patients. PARP inhibitors (olaparib maintenance) for BRCA1/2-mutated disease. Adjuvant chemotherapy after resection: modified FOLFIRINOX achieves median OS 54 months; gemcitabine + capecitabine is an alternative.

Is immunotherapy effective?

Pancreatic cancer is one of the most immunotherapy-resistant cancers — characterised by a highly immunosuppressive tumour microenvironment (dense stroma, M2 macrophages, Tregs, low mutational burden). Checkpoint inhibitors (pembrolizumab, nivolumab) show minimal activity in unselected pancreatic cancer. The exception: MSI-H/dMMR pancreatic cancer (approximately 1% of cases) responds to pembrolizumab. Novel approaches — tumour vaccines (KRAS neoantigen mRNA vaccines), combinations targeting the stroma and immune suppression — are in clinical trials.

What is new in pancreatic cancer research?

Key research developments: KRAS inhibitors — KRAS is mutated in >90% of PDAC; KRAS G12D inhibitors (the most common mutation in PDAC) are in trials; pan-RAS inhibitors; KRAS degraders; neoantigen mRNA vaccines (KRAS mutant-specific — early phase results promising); stroma targeting (hyaluronidase — the HALO-109-301 trial was negative but combinations are ongoing); ctDNA liquid biopsy for early detection and monitoring; and organoid models enabling personalised drug testing.

Who should have germline genetic testing?

All patients with pancreatic cancer should have germline genetic testing — guidelines from ASCO, ESMO and NCCN recommend this regardless of family history, age or tumour characteristics. Approximately 5-10% carry germline mutations (BRCA1/2, PALB2, ATM, MLH1/MSH2/MSH6). Identification of BRCA1/2 enables PARP inhibitor therapy; MLH1/MSH2 identifies MSI-H patients (pembrolizumab eligible); and all mutations enable family cascade testing for cancer prevention.

How does pancreatic cancer relate to diabetes?

The relationship between diabetes and pancreatic cancer is complex and bidirectional: long-standing type 2 diabetes (>10 years) modestly increases pancreatic cancer risk (~2-fold); conversely, pancreatic cancer frequently causes new-onset diabetes (paraneoplastic effect from tumour-induced beta cell dysfunction). New-onset diabetes in older adults (particularly males over 50 without obesity) warrants evaluation for pancreatic cancer — this "reverse causality" represents a potential window for earlier diagnosis.

How does GMJ News cover pancreatic cancer?

GMJ News tracks GLOBOCAN pancreatic cancer data, chemotherapy regimen trials, PARP inhibitor developments, KRAS inhibitor research, and early detection efforts. Pancreatic cancer's rising incidence — linked to obesity, diabetes and tobacco — makes it a growing concern in Georgia and directly relevant to PHIG's NCD prevention agenda.

Home › Topics › Pancreatic Cancer

Pancreatic Cancer

Q: What causes pancreatic cancer?

Risk factors: tobacco smoking (most important modifiable factor — 2-3 fold increased risk); chronic pancreatitis (10-fold increased risk); type 2 diabetes (2-fold risk — bidirectional relationship); obesity; heavy alcohol use; family history of pancreatic cancer; hereditary syndromes (BRCA1/2, Lynch syndrome, hereditary pancreatitis — PRSS1 mutations, SPINK1); and high-fructose diet (possible). Approximately 10% of pancreatic cancers are hereditary.

Q: What are the symptoms?

Early pancreatic cancer is entirely asymptomatic — symptoms only appear when the tumour is large enough to cause biliary or duodenal obstruction, or when it has metastasised. Symptoms: painless jaundice (from bile duct obstruction — actually a relatively favourable sign indicating a ductal tumour amenable to surgery); abdominal or back pain (from retroperitoneal invasion — indicates unresectable disease); weight loss; new-onset diabetes (particularly in older patients without other risk factors — a potential early warning); and nausea.

Q: Can pancreatic cancer be detected early?

Currently, there is no validated screening test for average-risk individuals. CA 19-9 lacks specificity for early detection. High-risk surveillance — annual MRI/MRCP and endoscopic ultrasound (EUS) — is recommended for individuals with >5% lifetime risk: BRCA1/2, PALB2, ATM, MLH1/MSH2/MSH6 mutation carriers; hereditary pancreatitis; Peutz-Jeghers syndrome; and familial pancreatic cancer kindreds. Liquid biopsy (ctDNA, cell-free DNA) and AI-based imaging analysis are research strategies for early detection.

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Pancreatic cancer is one of medicine's most urgent unresolved challenges: with approximately 495,000 new cases and 466,000 deaths in 2020 — a nearly 1:1 incidence-to-mortality ratio — it has a 5-year survival rate of only 12%, making it the cancer with the poorest prognosis of any major tumour type (IARC GLOBOCAN 2020). Most cases are diagnosed at advanced stage because early-stage pancreatic cancer is asymptomatic, and no reliable screening test exists. The FOLFIRINOX and gemcitabine + nab-paclitaxel chemotherapy regimens, alongside PARP inhibitors for BRCA-mutant tumours and immunotherapy trials, represent the current treatment frontier.

Key messages

Near 1:1 incidence-mortality ratio

Pancreatic cancer had 495,000 new cases and 466,000 deaths in 2020 — a nearly 1:1 ratio that reflects its dismal prognosis. It is the cancer with the poorest outcomes of any major tumour type, with an overall 5-year survival of only 12% (IARC GLOBOCAN 2020).

Late diagnosis is the core problem

Most pancreatic cancers are diagnosed at advanced stage — when curative surgery is no longer possible. This is because early-stage pancreatic cancer is entirely asymptomatic, and there is no validated screening test for average-risk individuals.

Rising incidence

Pancreatic cancer incidence is rising globally — driven by increasing rates of obesity, type 2 diabetes, excessive alcohol, heavy smoking and — possibly — high-fructose diets. It is projected to become the 2nd leading cause of cancer death in high-income countries by 2030.

Surgical cure is possible only for early-stage

Surgical resection (the Whipple procedure or distal pancreatectomy) offers the only chance of cure — but is applicable to only approximately 15-20% of patients at diagnosis. Five-year survival after resection with clear margins can reach 20-25%.

FOLFIRINOX transformed metastatic treatment

The FOLFIRINOX (oxaliplatin + irinotecan + leucovorin + fluorouracil) regimen and gemcitabine + nab-paclitaxel have improved median survival in metastatic disease to approximately 11-12 months — still critically insufficient.

BRCA/PARP inhibitors

Approximately 5-7% of pancreatic cancers carry BRCA1/BRCA2 mutations — sensitising them to PARP inhibitors (olaparib as maintenance after platinum-based chemotherapy). Germline testing is recommended for all pancreatic cancer patients.

Key statistics

495K

new pancreatic cancer cases/year (2020)

IARC GLOBOCAN

466K

pancreatic cancer deaths/year (2020)

IARC GLOBOCAN

12%

overall 5-year survival

SEER/GLOBOCAN

<5%

5-year survival — metastatic stage

SEER

15-20%

of patients eligible for surgical resection

ESMO/ASCO

projected cause of cancer death in HICs by 2030

Research projection

Pancreatic cancer new cases vs deaths globally — GLOBOCAN 2020 comparison with other cancers

Source: IARC GLOBOCAN 2020. Pancreatic cancer's nearly 1:1 incidence-to-mortality ratio is unique among major cancers.

Glossary of key terms

Pancreatic ductal adenocarcinoma (PDAC)
WHO/ESMOThe most common pancreatic cancer type (~90% of cases) — arising from exocrine pancreatic ductal cells. Characterised by dense desmoplastic stroma limiting drug delivery; near-universal KRAS mutations (>90%); TP53 (72%), SMAD4 (32%), CDKN2A mutations; and median overall survival of 11-12 months with first-line chemotherapy.

Whipple procedure
Surgery/WHOPancreaticoduodenectomy — the major surgical resection for pancreatic head cancers. Removes the head of the pancreas, duodenum, part of the bile duct, gallbladder and sometimes part of the stomach. Complex surgery with 5-6% mortality in high-volume centres; 3-6 month recovery. Only potentially curative option.

CA 19-9
WHO/ASCOCarbohydrate antigen 19-9 — the most widely used pancreatic cancer biomarker. Elevated in approximately 80% of pancreatic cancer. Used for monitoring treatment response and recurrence, but not suitable for early detection (poor specificity — also elevated in biliary obstruction, pancreatitis).

FOLFIRINOX
ESMO/ASCOA chemotherapy regimen — oxaliplatin + irinotecan + leucovorin + fluorouracil — that significantly improved metastatic pancreatic cancer survival vs gemcitabine alone in the PRODIGE 4/ACCORD 11 trial. Given to fit patients (ECOG 0-1); median OS approximately 11 months.

KRAS G12C inhibitor
FDA/researchKRAS G12C mutations are present in approximately 1-2% of pancreatic cancers (vs approximately 40% in NSCLC). KRAS G12C inhibitors (sotorasib, adagrasib) have limited activity in pancreatic cancer. Pan-RAS and KRAS G12D inhibitors are in development for the KRAS G12D mutation present in approximately 40% of PDAC.

PARP inhibitor maintenance
FDA/ESMOOlaparib maintenance after platinum-based chemotherapy for BRCA1/2-mutated metastatic pancreatic cancer — significantly improved progression-free survival in the POLO trial. Recommended for the approximately 5-7% of pancreatic cancer patients with BRCA mutations. Germline genetic testing recommended for all patients.